Novartis India announces results for the quarter and year ended March 31, 2013
Net sales/ income from operations is reported at Rs 212.9 crores
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
DRL posts consolidated revenues for FY 13 at Rs 116.3 billion
EBITDA margins posted at Rs 27.8 billion in FY13
Countries must fix critical access to medicines flaws in Trans-Pacific Trade Pact: MSF
Access to medicines issues finally back on negotiators’ agenda after being sidelined for more than a year
Sathguru and RTI International’s vaccine delivery solution bag recognition
Receives Grand Challenges Canada with a grant of CAD 100,000
Piramal Enterprises receives IND approval from the US FDA for its anti-diabetic molecule
Will enable to initiate a phase I clinical trial of P11187
Unichem Laboratories adjusted PAT grows 33.1 per cent
Domestic formulations business grows 27.8 per cent
Lupin deploys Microsoft Office 365, manages significant cost reductions
Enables its 11,000 employees to communicate more effectively and efficiently
Ranbaxy announces conclusion of previously disclosed investigation by US Department of Justice
Investigation of data integrity and manufacturing processes at certain Ranbaxy facilities were concluded
Novartis Biotechnology Leadership Camp to be held in Hyderabad
Three winning students from India to participate in the International Novartis Biotechnology Leadership Camp at Basel, Switzerland…
SPDS organises international convention on dissolution in Mumbai
Disso India 2013 attended by more than 300 delegates